Clearside Biomedical (FRA:CLM) ROCE % : -88.83% (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Clearside Biomedical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Clearside Biomedical's annualized ROCE % for the quarter that ended in Dec. 2024 was -88.83%.

Clearside Biomedical ROCE % Historical Data

The historical data trend for Clearside Biomedical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearside Biomedical ROCE % Chart

Clearside Biomedical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-136.11

1.60

-72.75

-62.45

-105.79

Clearside Biomedical Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-36.23	-122.13	-67.88	-79.71	-88.83

Clearside Biomedical ROCE % Calculation

Clearside Biomedical's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-23.467	/	( ( (31.195 - 6.248)	+	(23.995 - 4.578) )	/ 2 )
	=	-23.467	/	( (24.947	+	19.417)	/ 2 )
	=	-23.467	/	22.182
	=	-105.79 %

Clearside Biomedical's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-18.056	/	( ( (26.274 - 5.039)	+	(23.995 - 4.578) )	/ 2 )
	=	-18.056	/	( ( 21.235	+	19.417 )	/ 2 )
	=	-18.056	/	20.326
	=	-88.83 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Clearside Biomedical (FRA:CLM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Clearside Biomedical ROCE % Related Terms

Thank you for viewing the detailed overview of Clearside Biomedical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Clearside Biomedical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearside Biomedical Inc (FRA:CLM) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CLSD:USA CLM:Germany

Address

900 North Point Parkway, Suite 200, Alpharetta, GA, USA, 30005

Website

https://www.clearsidebio.com

Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.